2021 HBV-TAG CONFERENCE
PRESENTATION SLIDES

Friday, June 11, 2021 

Title.jpg

The Year in Review

Presenter:  Raymond Chung, MD 

Title.jpg

Global Status of Hepatitis B 

Presenter:  Brian McMahon, MD

  

SESSION 1: New Perspectives on HBV Virology 

Title.jpg

Update: The HBV Entry

Presenter: Stephan Urban, PhD

Title.jpg

Biology of cccDNA: Formation, Maintenance, and Regulation 

Presenter: Haitao Guo, PhD

Title.jpg

Role of HBx on Transcriptional Regulation of HBV cccDNA 

Presenter: Rudolf Beran, PhD 

Title.jpg

HBV Integration: Consequences for Viral Gene Expression and Cellular Gene Dysregulation

Presenter: Thomas Tu, PhD 

SESSION 2: Evaluation of HBV Infected Patients: Current Practice and New Horizons 

Title.jpg

Noninvasive Assessment of Fibrosis in Hepatitis B 

Presenter: Richard Sterling, MD, MSc 

Title.jpg

Genotypes, Core and Precore Mutations 

Presenter: Brian McMahon, MD

SESSION 3: New Perspectives on HBV Virology 

Title.jpg

Impact of Current Treatment on Incidence of HCC 

Presenter: Raymond Kim, MD, MBA, FAASLD 

Title.jpg

Screening and Surveillance Debate

Presenters: Ira Jacobson, MD and Amit Singal, MD 

Title.jpg

Molecular Genetics of HCC: When Should Tumor Genomic Sequencing be Done?

Presenter: Lewis Roberts, M.B., CH.B., PH.D.

SESSION 4: Controversies in Current Therapy

Title.jpg

When Should We Stop Nuc Therapy? HBeAg+, HBeAg-

Presenter: Harry Janssen, MD, PhD

Title.jpg

Flares: Good, Bad, or Just Ugly?

Presenter: Robert Fontana, MD

Title.jpg

Is there a Role for Interferon with Nucleos(t)ides?

Presenter: Robert Perrillo, MD 

Title.jpg

Blazing Saddles Expanding Treatment Criteria

Presenter: Patrick Kennedy, MD

SESSION 5: Controversies in Current Therapy

Title.jpg

Capsid Assembly Modulators 

Presenter: Man Fung (MF) Yuen, MD, PhD 

Title.jpg

Other Antiviral Approaches Including FXR, HBxAg and RNA Destabilizers and Beyond 

Presenter: Fabien Zoulim, MD, PhD  

Title.jpg

siRNAs and Antisense Oligonucleotides 

Presenter: Edward Gane, MD 

Title.jpg

CRISPR and other DNA Targeting Approaches 

Presenter: Ype de Jong, MD, PhD  

Title.jpg

Approaches to Target HBsAg from cccDNA or Integrates 

Presenter: George Wu, MD, PhD 

Saturday, June 11, 2021 

SESSION 6: Immune-Based Therapies 

Title.jpg

New Perspectives on HBV Immunology 

Adam Gehring, PhD

Title.jpg

Innate Immunity: TLR, STING 

Presenter: Ju-Tao Guo, MD  

Title.jpg

Adaptive Immunity: T-Cell Therapies 

Antonio Bertoletti, MD 

Title.jpg

Adaptive Immunity: B-Cell Therapies 

Mala Maini, MD, PhD

SESSION 7: HBV Drug Development – General Considerations 

Title.jpg

Lessons Learned from HBV and Other Drugs and Technology Development in Hepatology 

Presenter: Nid Afdhal, MD

Title.jpg

Is There a Role for Tissue Sampling and Machine Learning in Studies of Novel HBV Therapies? 

Presenter: Jordan Feld, MD

Title.jpg

Pharmacoeconomic Considerations in Hepatitis B Drug Development

Presenter: Sammy Saab, MD 

SESSION 8: Hepatitis D

Title.jpg

HDV Epidemiology, Life Cycle and Targets of Therapeutic Interference 

Presenter: Jeffrey Glenn, MD, PhD 

Title.jpg

Lonafarnib and Lambda Interferon

Presenter: Christopher Koh, MD, M.H.Sc. 

Title.jpg

Bulevirtide 

Presenter: Heiner Wedemeyer, MD 

Title.jpg

Other HBV Targets that will affect HDV Replication or Release  

Presenter: Timothy Block, PhD

 

SESSION 9: Advocacy 

Title.jpg

Hepatitis B Foundation Survey on What the Patients Want Out of New Hepatitis B 

Drug Development 

Presenter: Chari Cohen, DrPH, MPH 

Title.jpg

Quality-of-Life, Extrahepatic Manifestations 

Presenter: David Bernstein, MD 

Title.jpg

Stigma

Presenter: Robert Gish, MD